Retatrutide Guide: What It Is, How It Works, and Why People Are Watching It

Retatrutide is one of the most talked-about weight-loss drugs that is not fully on the market yet. That matters. People hear about it online, see dramatic claims, and assume it is just another version of Ozempic or Mounjaro. It is not. Retatrutide is a different drug that is still investigational — but it now has real Phase 3 trial results behind it.

What retatrutide is

Retatrutide is a next-generation drug being studied for obesity and metabolic health. It is made by Eli Lilly. It works on three pathways:

GLP-1 — signals fullness, slows digestion
GIP — works with GLP-1 to boost the effect
glucagon — increases energy expenditure (burns more calories)

That is why people call it a triple agonist. It is the first drug in this category to target all three receptors at once.

Does retatrutide have a brand name?

No approved retail brand name at this time. That is one of the easiest ways to tell retatrutide apart from semaglutide and tirzepatide.

Semaglutide brand names

Ozempic
Wegovy
Rybelsus

Tirzepatide brand names

Mounjaro
Zepbound

Retatrutide brand names

none approved yet

Why people are paying attention to retatrutide

Because the Phase 3 results are in — and they are strong. Two major trials have now reported results:

TRIUMPH-4 (obesity + knee osteoarthritis)

This was the first Phase 3 trial to report. Results came out in December 2025. The trial ran for 68 weeks in people with obesity and knee osteoarthritis (no diabetes).

	Retatrutide 9 mg	Retatrutide 12 mg	Placebo
Weight loss	26.4% (avg 64.2 lbs)	28.7% (avg 71.2 lbs)	2.1%
Knee pain reduction (WOMAC)	75.8%	74.3%	40.3%
Reached 25% weight loss	47.7%	58.6%	1.3%
Reached 30% weight loss	30.5%	39.4%	0.8%

That 28.7% number is the highest average weight loss reported in any Phase 3 obesity trial so far. Some patients lost more than a third of their body weight.

The knee pain improvement was also notable. More than 1 in 8 patients on retatrutide were completely free of knee pain by the end of the trial.

TRANSCEND-T2D-1 (type 2 diabetes)

Results reported in March 2026. This trial ran for 40 weeks in adults with type 2 diabetes who were not on other diabetes medications.

	Retatrutide 4 mg	Retatrutide 9 mg	Retatrutide 12 mg	Placebo
A1C reduction	1.7%	2.0%	1.9%	0.8%
Weight loss	11.5% (24.5 lbs)	15.5% (33.3 lbs)	16.8% (36.6 lbs)	2.5% (6.2 lbs)

One important finding: weight loss kept going through the full 40 weeks. There was no plateau. That suggests longer treatment could lead to even more weight loss.

Both trials also showed improvements in cardiovascular risk factors like blood pressure, cholesterol, and inflammation markers.

Retatrutide vs semaglutide vs tirzepatide

Here is the plain-English version:

Semaglutide

one main pathway: GLP-1
sold as Ozempic, Wegovy, Rybelsus
Phase 3 weight loss: around 15% (Wegovy)

Tirzepatide

two pathways: GLP-1 + GIP
sold as Mounjaro, Zepbound
Phase 3 weight loss: around 21% (Zepbound)

Retatrutide

three pathways: GLP-1 + GIP + glucagon
no approved retail brand name yet
Phase 3 weight loss: up to 28.7% (TRIUMPH-4)

That does not tell you which one is "best" for any one person. But the numbers explain why retatrutide gets so much attention. The added glucagon pathway appears to push weight loss beyond what the current drugs achieve.

What does the glucagon part mean?

This is where articles often get too technical. The simple version is:

Retatrutide is being studied as a more aggressive metabolic drug. The glucagon receptor increases energy expenditure — meaning your body burns more calories even at rest. That is on top of the fullness and appetite signals from GLP-1 and GIP.

That does not automatically mean better for everyone. It means the drug is trying to affect the body in a broader way than semaglutide or tirzepatide alone.

Side effects and safety

The most common side effects in the Phase 3 trials were the same ones you see with other GLP-1 drugs:

nausea
diarrhea
constipation
vomiting
decreased appetite

These were mostly mild to moderate and happened most during dose increases.

A new side effect worth knowing about

The trials also reported dysesthesia — a tingling, burning, or numb sensation, usually mild. This showed up in both Phase 3 trials:

TRIUMPH-4: 8.8% (9 mg) and 20.9% (12 mg) vs 0.7% with placebo
TRANSCEND-T2D-1: 2.3% to 4.5% vs 0% with placebo

Most cases were mild and did not cause people to stop the drug. But this is a new signal that researchers are watching.

Discontinuation rates

In TRIUMPH-4, more people stopped the drug due to side effects at the highest dose:

12.2% (9 mg) and 18.2% (12 mg) vs 4.0% with placebo

Some of those discontinuations were actually because people felt they had lost too much weight. For people with a BMI of 35 or higher, the discontinuation rates were lower: 8.8% and 12.1% vs 4.8% with placebo.

In TRANSCEND-T2D-1, discontinuation was much lower: 2.2% to 5.1% vs 0% with placebo.

Is retatrutide available now?

Not as a normal approved retail medication. But the situation has changed from a year ago. Retatrutide now has two successful Phase 3 trials. Seven more Phase 3 trials are still running and results are expected throughout 2026.

Here is what the timeline looks like:

December 2025: TRIUMPH-4 results (obesity + knee osteoarthritis) — positive
March 2026: TRANSCEND-T2D-1 results (type 2 diabetes) — positive
2026 (ongoing): Seven more Phase 3 readouts expected, including trials for general obesity, obstructive sleep apnea, cardiovascular outcomes, and liver disease
June 2026: Detailed TRANSCEND-T2D-1 results at the American Diabetes Association Scientific Sessions
Earliest likely FDA filing: Late 2026 or 2027, after the remaining Phase 3 trials finish
Earliest possible approval: 2027 at the soonest

This is an estimate, not a guarantee. Lilly has not announced a specific filing date. The FDA process itself typically takes 6 to 10 months after a filing.

Phase 3 Trial Status (April 2026 Update)

This is the most important new information.

What Phase 3 Means

Phase 3 is the last stage of clinical trials before a drug can be submitted to the FDA for approval. It involves large numbers of patients and is designed to confirm that the drug works and is safe.

Current Status

Eli Lilly is running Phase 3 trials for retatrutide in obesity and type 2 diabetes
The obesity trial (called TRUMPH-2) is enrolling patients and collecting data
The diabetes trial is also in Phase 3
Full results have not been published yet

What Early Data Showed

Phase 2 trial results were encouraging:

Patients on the highest dose lost up to 24% of body weight over 48 weeks
This was more weight loss than seen in semaglutide or tirzepatide trials at similar timepoints
Side effects were similar to other GLP-1 drugs (mostly nausea and GI issues)

Important caveat: Phase 2 results do not always match Phase 3 results. Do not assume the final data will look exactly the same.

Expected Timeline

Here is what the timeline likely looks like:

Phase 3 completion — Expected late 2026 or early 2027
FDA submission — Could happen in late 2026 or early 2027 if trials go well
FDA review — Typically takes 6-10 months after submission
Earliest possible approval — Mid-to-late 2027

These are estimates. Drug development timelines often shift. Do not make medical decisions based on an assumed approval date.

Safety Signals So Far

The safety profile in trials looks similar to other GLP-1 medications:

Nausea — most common, dose-dependent
Diarrhea and vomiting — frequent in early dosing
Constipation — reported by some patients
Injection site reactions — mild, uncommon

No major unexpected safety signals have been reported so far, but full Phase 3 safety data is not yet available.

Why this article needs caution

Retatrutide content gets weird fast online. You will see:

hype
rumor
people acting like approval already happened
people talking about it like it is the obvious winner before the dust has settled

The Phase 3 results are genuinely strong. But the smart view is still:

yes, it is interesting — more than ever
yes, the trial numbers are real
no, that does not make every dramatic claim true
no, you cannot get it at a pharmacy yet

What questions people usually have

Most readers are trying to answer one of these:

What is retatrutide?
Is retatrutide better than semaglutide?
Is retatrutide better than tirzepatide?
Does retatrutide have a brand name?
Can you actually get retatrutide yet?
When will retatrutide be approved?

The clean answer right now:

Retatrutide is a triple-agonist investigational drug with strong Phase 3 results. It does not have an approved brand name yet, and it should not be discussed like it is already just another routine retail GLP medication. The earliest it could reach patients is 2027.

Products That Can Help

Learning about upcoming GLP medications? These products may help you prepare:

GLP-1 starter guide book — Understand current options while new drugs develop
Smart scale with body composition — Track progress with current treatments
Food and weight journal — Document what works for your body
Protein powder — Support muscle preservation on any GLP medication

Bottom line

Retatrutide matters because it may represent the next wave of obesity and metabolic drugs. The Phase 3 data so far shows the highest weight loss numbers seen in this drug class. But right now, the honest way to think about it is:

it is real
it is important
it is in Phase 3 clinical trials (as of April 2026)
the trial results are strong
it does not have an approved brand name yet
the earliest possible approval is likely 2027
do not make medical decisions based on an assumed timeline

If you want to compare it with what is already available, read next:

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug that is not yet approved by the FDA. Talk to your healthcare provider about treatment options that are right for you.